Rosacea

CollaGenex Pharmaceuticals Reports Financial Results for the Second Quarter and First Half of 2007

Published in Medical Letter on the CDC and FDA, August 26th, 2007

CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) reported financial results for the second quarter and six months ended June 30, 2007.

Net revenues were $16.4 million in the second quarter of 2007 compared to $3.8 million in the second quarter of 2006, reflecting significantly higher net product sales following the July 2006 launch of Oracea(R), the only FDA-approved systemic treatment of rosacea. Net sales of Oracea were $13.1 million in the second quarter of 2007.

Net loss allocable to common stockholders for the second quarter of 2007 was $4.8 million, or $0.23 per basic and diluted share, compared to a net loss allocable to common stockholders of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2007-08-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry